Last reviewed · How we verify
clopidogrel/abciximab
This combination uses clopidogrel to inhibit platelet aggregation via P2Y12 receptor blockade and abciximab to block the glycoprotein IIb/IIIa receptor, providing dual antiplatelet effects.
This combination uses clopidogrel to inhibit platelet aggregation via P2Y12 receptor blockade and abciximab to block the glycoprotein IIb/IIIa receptor, providing dual antiplatelet effects. Used for Acute coronary syndrome and percutaneous coronary intervention.
At a glance
| Generic name | clopidogrel/abciximab |
|---|---|
| Also known as | Plavix, ReoPro |
| Sponsor | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio |
| Drug class | Dual antiplatelet agent (P2Y12 inhibitor + glycoprotein IIb/IIIa inhibitor) |
| Target | P2Y12 receptor (clopidogrel); glycoprotein IIb/IIIa integrin (abciximab) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Clopidogrel is a thienopyridine that irreversibly inhibits the P2Y12 adenosine diphosphate receptor on platelets, preventing platelet activation and aggregation. Abciximab is a chimeric monoclonal antibody that binds to the glycoprotein IIb/IIIa integrin receptor on platelets, blocking fibrinogen binding and platelet cross-linking. Together, they provide complementary antiplatelet mechanisms to prevent thrombotic events.
Approved indications
- Acute coronary syndrome and percutaneous coronary intervention
Common side effects
- Bleeding
- Thrombocytopenia
- Hypersensitivity reactions
Key clinical trials
- Aspirin Resistance and Percutaneous Coronary Intervention (PCI) (PHASE2)
- Tailored Antiplatelet Therapy During Percutaneous Coronary Intervention in Patients With Diabetes Mellitus (PHASE4)
- Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI (PHASE4)
- Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3) (PHASE4)
- Efficacy of Abciximab Bolus Only Regimen in Providing Inhibition of Platelet Action Over Time (PHASE4)
- Beyond 12 Hours Reperfusion AlternatiVe Evaluation Trial (PHASE4)
- Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- clopidogrel/abciximab CI brief — competitive landscape report
- clopidogrel/abciximab updates RSS · CI watch RSS
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio portfolio CI